arrow
D

David Liu

Dana-Farber Cancer Institute
H指数:62
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: Specific oncogene activation of the cell of origin in mucosal melanoma

作者更正:黏膜黑色素瘤起源细胞的特异性癌基因激活

2026-08-200
OAAI
Understanding tumor-immune-stromal dynamics driving response and resistance to immune checkpoint blockade in melanoma
2025-11-010
PRE
Comparative Analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model

CRISPR-Cas9、慢病毒转导和碱基编辑技术在镰状细胞病小鼠模型中的比较分析

2025-10-300
OAAI
Policies, resource allocation, and interventions for child and adolescent mental health in low- and middle-income countries in the Western Pacific Region: a scoping review

西太平洋地区中低收入国家儿童和青少年心理健康政策、资源配置与干预措施:一项范围综述

2025-09-030
OAAI
Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma

成熟和迁移的树突状细胞促进免疫浸润以及对转移性黑素瘤中抗PD-1检查点阻断的应答

2025-09-010
OAAI
Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants

通过靶向CD38克服人类肿瘤移植组织对免疫治疗的抵抗

2025-06-270
OAAI
Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab
2024-12-191
OAAI
Automated real-world data integration improves cancer outcome prediction

自动化的真实世界数据集成可改善癌症结果预测

Nature
IF48.5
2024-11-060
OAAI
Spatial single-cell deconvolution of the bone marrow microenvironment to define predictive biomarker for response to immunotherapy in patients treated with a check point inhibitor in smoldering multiple myeloma, phase II trial of nivolumab in combination with lenalidomide and low dose dexamethasone
2024-03-220
PRE
Dissecting tumor- immune interaction in response and resistance to immune checkpoint blockade in metastatic melanoma
2024-03-220
PRE
Immune profiling for improving responsiveness to ipilimumab plus nivolumab checkpoint blockade treatment in patients with metastatic melanoma
2024-03-220
PRE